Trump's Groundbreaking Directive Ignites Firestorm of Growth for Enveric Biosciences Shares, Surging Over 160%

Table of Contents Shares of psychedelic biotechnology companies surged Monday following President Trump’s weekend executive order directing federal health authorities to accelerate review timelines for psychedelic-based medical treatments. Enveric Biosciences (ENVB) dominated the rally, closing the trading day with gains exceeding 160% — a remarkable performance for a company carrying a market capitalization of merely $3.43 million. Enveric Biosciences, Inc., ENVB The executive order took a sector-wide approach rather than targeting specific companies. It represented a sweeping mandate to the FDA and affiliated regulatory bodies to streamline approval pathways for psychedelic therapeutics. The announcement proved sufficient to propel virtually every publicly traded psychedelic biotech stock higher. AtaiBeckley (ATAI) surged 28.1% during premarket activity. Compass Pathways (CMPS) rose 26.1%. Definium Therapeutics (DFTX) climbed 14.6%. GH Research (GHRS) advanced 19.7%. The bullish momentum permeated throughout the entire sector. In addition to the regulatory directive, President Trump announced a $50 million funding allocation specifically for ibogaine research initiatives. Ibogaine represents a psychoactive substance extracted from African plant sources and remains classified as Schedule I under U.S. federal law — designating it as having no accepted medical applications. The funding commitment represents a notable policy pivot regarding mental health treatment approaches, particularly concerning post-traumatic stress disorder. Preliminary research has demonstrated ibogaine’s potential therapeutic benefits for PTSD sufferers, with particular promise for military veteran populations. Compass Pathways CEO Kabir Nath publicly praised the executive action, stating it “recognizes the profound urgency of the mental health crisis facing millions of Americans.” Brian Abrahams, an analyst at RBC, supported this assessment, characterizing the directive as “a substantial step towards diminishing regulatory risk” facing psychedelic therapeutic development. ENVB’s dramatic price appreciation occurred against an important backdrop. The company had recently completed a $5 million private placement just days prior — a capital raise that actually exceeded the firm’s total market capitalization at that time. The financing involved selling 2,222,223 shares priced at $2.25 apiece, accompanied by two separate warrant series carrying a $2.00 per share exercise price. The company’s primary development candidate, designated EB-003, targets both 5-HT2A and 5-HT1B receptor systems and is undergoing development for various psychiatric and neurological indications. Recently disclosed mechanistic studies demonstrated that EB-003 activates dual signaling mechanisms associated with antidepressant and anxiolytic therapeutic effects. ENVB has also secured U.S. patent protection encompassing its EVM301 molecular compounds, which include the EB-003 candidate, alongside Canadian trademark approvals for five brand marks including “Enveric” and “Next Generation Mental Health.” Should investors exercise both warrant series issued through the private placement fully, the company stands to receive approximately $8.9 million in additional gross capital. Monday’s stock movement — surpassing 160% — captured both the favorable regulatory tailwind generated by the executive order and the strategic timing of recent fundraising activities that extended the company’s operational runway precisely when this catalytic policy shift materialized.